WO1989001934A1 - Hydantoin derivatives - Google Patents

Hydantoin derivatives Download PDF

Info

Publication number
WO1989001934A1
WO1989001934A1 PCT/JP1988/000843 JP8800843W WO8901934A1 WO 1989001934 A1 WO1989001934 A1 WO 1989001934A1 JP 8800843 W JP8800843 W JP 8800843W WO 8901934 A1 WO8901934 A1 WO 8901934A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
solvates
integer
toxic salts
hydantoin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1988/000843
Other languages
English (en)
French (fr)
Inventor
Ei Mochida
Kazuo Kato
Katsuaki Kato
Ichitomo Miwa
Jun Okuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of WO1989001934A1 publication Critical patent/WO1989001934A1/en
Priority to FI891933A priority Critical patent/FI97134C/fi
Priority to NO89891689A priority patent/NO173059C/no
Priority to DK207389A priority patent/DK207389A/da
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel hydantoin derivatives, processes for producing hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.
  • Cataract, peripheral neuropathy, retinopathy and nephropathy associated with diabetes mellitus result from abnormal accumulation of polyol metabolites converted from sugars by aldose reductase.
  • sugar cataract results from damage of lens provoked by change in osmotic pressure induced by abnormal accumulation of polyol metabolites converted from glucose or galactose by aldose reductase in lens. Consequently, it is important to inhibit aldose reductase as strongly as possible for treating and/or preventing diabetic complications mentioned above.
  • aldose reductase inhibitors none of them is fully sufficient in inhibitory activity against the enzyme. Therefore, it has been desired to develop new compounds having a stronger inhibitory activity against aldose reductase.
  • An object of the present invention is to provide novel hydantoin derivatives and salts, solvates and solvates of salts thereof.
  • Another object of the present invention is to provide processes for producing said novel hydantoin derivatives.
  • a further object of the present invention is to provide pharmaceutical compositions comprising at least one of said novel hydantoin derivatives having an inhibitory activity against aldose reductase.
  • a further object of the present invention is to provide novel intermediate compounds in the synthesis of said novel hydantoin derivatives.
  • the present inventors have made extensive researches on a series of compounds having an inhibitory activity against aldose reductase and found novel hydantoin derivatives having an extremely strong inhibitory activity against aldose reductase. They are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
  • the present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.
  • the present invention is directed to novel hydantoin derivatives represented by the general formula (I):
  • the present invention is also directed to the process for preparing above-mentioned hydantoin derivatives.
  • the present invention is further directed to pharmaceutical compositions characterized by containing at least one of these hydantoin derivatives as active component (s).
  • the present invention is further directed to novel intermediate compounds in the synthesis of above- mentioned hydantoin derivatives.
  • hydantoin derivatives of the present invention represented by the general formula (I), it is known that the hydantoin moiety exhibits tautomerism as shown below:
  • the compounds represented by the general formula (I) may form salts with base.
  • Typical examples of salts with base of the compounds represented by the general formula (I) include pharmaceutically acceptable salts such as alkali metal salts (such as sodium salts, potassium salts, etc.), alkaline earth metal salts (such as calcium salts, etc.), salts with organic bases (such as ammonium salts, benzylamine salts, diethylamine salts, etc.) or salts of amino acids (such as arginine salts, lysine salts, etc.).
  • These salts of the compounds represented by the general formula (I) may be mono-salts or di-salts which may be salts of the hydantoin moiety and/or salts of the carboxy group contained in the Q group.
  • the compounds represented by the general formula (I) may also form acid addition salts.
  • Typical example of acid addition salts of the compounds represented by the general formula (I) include pharmaceutically acceptable salts, such as salts of inorganic acids (such as hydrochlorides, hydrobromides, sulfates, phosphates, etc.), salts of organic acids (such as acetates, citrates, maleates, tartrates, benzoates, ascorbate, ethanesulfonates, toluenesulfonates, etc.) or salts of amino acids (such as aspartates, glutamates, etc.).
  • These salts of the compounds represented by the general formula (I) may be salts of the heterocyclic moiety in the Q group .
  • the lower alkyl group can be defined more specifically as a straight or branched lower alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, isopropyl, tert-butyl, etc.
  • the alkoxy group can be defined more specifically as a straight or branched lower alkoxy group having 1 to 4 carbon atoms such as methoxy, ethoxy, isopropoxy, tert-butoxy, etc.
  • the acyl group can be defined more specifically as a straight or branched lower acyl group having 1 to 5 carbon atoms such as formyl, acetyl, propanoyl, butanoyl, pivaloyl, etc.
  • the heterocyclic group can be defined as a monocyclic heterocyclic group such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl, thiatriazolyl, thienyl, furyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, pyridyl or its N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, triazinyl, etc., or a fused heterocyclic group such as indolyl, isoindolyl,
  • heterocyclic groups may be substituted with a group such as a lower alkyl group (such as methyl, ethyl, isopropyl, tert-butyl, etc.), an acyl group (such as formyl, acetyl, propanoyl, butanoyl, pivaloyl, etc.), an alkoxy group (such as methoxy, ethoxy, isopropoxy, tert- butoxy, etc.), an aryl group, a cyano group, a carboxy group, a nitro group or a halogen atom (such as fluoro, chloro, bromo, etc.), or combination of any of these groups.
  • a lower alkyl group such as methyl, ethyl, isopropyl, tert-butyl, etc.
  • an acyl group such as formyl, acetyl, propanoyl, butanoyl, pivaloyl, etc.
  • the compounds of the present invention represented by the general formula (I) can be produced by the processes described as follows. Namely;
  • R 2 represents a hydroxy group, an alkoxy group or an amino group which may be substituted with an alkoxycarbonyl group, to give the corresponding sulfonylglycine derivative represented by the general formula (IV):
  • the condensation reaction is carried out generally in an aqueous solution, in an organic solvent (such as dichloromethane, chloroform, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, etc.) or in a mixed solvent of an aqueous solution and an organic solvent, preferably in the presence of deacidifying agent.
  • an organic solvent such as dichloromethane, chloroform, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, etc.
  • deacidifying agent triethylamine, diethylaniline, pyridine, etc.
  • aqueous alkali such as sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, etc.
  • the condensation reaction is carried out at temperatures ranging from about -20 to 80°C, preferably 0°C to room temperature.
  • R 2 represents an amino group in the general formula (IV)
  • the sulfonylglycine derivative is represented by the general formula (IV'):
  • the sulfonylglycine derivative represented by the general formula (IV) is cyclized using a haloformic acid ester (such as methyl chloroformate, ethyl chloroformate, etc.) in the presence of a base (such as sodium hydride, potassium hydride, butyl lithium, etc.) to give the corresponding hydantoin derivative of the present invention represented by the general formula (I).
  • a haloformic acid ester such as methyl chloroformate, ethyl chloroformate, etc.
  • a base such as sodium hydride, potassium hydride, butyl lithium, etc.
  • the cyclization reaction is carried out generally in an inert solvent (such as N,N-dimethylformamide, dimethylsulfoxide, ethyl ether, tetrahydrofuran, dioxane, dichloromethane, etc.) and at temperatures ranging from about -20 to 120oC, preferably 0 to 80oC.
  • an inert solvent such as N,N-dimethylformamide, dimethylsulfoxide, ethyl ether, tetrahydrofuran, dioxane, dichloromethane, etc.
  • the sulfonylglycine derivative represented by the general formula (IV") is cyclized with a thiocyanate derivative (such as ammonium thiocyanate, potassium thiocyanate, etc.) in the presence of an acid anhydride (such as acetic anhydride, propionic anhydride, etc.) and, if necessary and desired, a base (such as pyridine, triethylamine, etc.) to give the corresponding 2-thiohydantoin derivative.
  • a thiocyanate derivative such as ammonium thiocyanate, potassium thiocyanate, etc.
  • an acid anhydride such as acetic anhydride, propionic anhydride, etc.
  • a base such as pyridine, triethylamine, etc.
  • the cyclization reaction is carried out after hydrolysis of ester when R 2 represents an alkoxy group.
  • the cyclization reaction is carried out generally in an inert solvent (such as pyridine, triethylamine, N,N-dimethylformamide, dimethylsulfoxide, etc.) and at temperatures ranging from 0 to 120 °C, preferably room temperature to 100oC.
  • an inert solvent such as pyridine, triethylamine, N,N-dimethylformamide, dimethylsulfoxide, etc.
  • oxidizing agent such as nitric acid, chlorine, iodine chloride, potassium permanganate, hydrogen peroxide, dimethylsulfoxide-sulfuric acid, etc.
  • the inhibitory activities of hydantoin derivatives on rat lens aldose reductase were measured according to the procedure of Inagaki et al. (K. Inagaki et al., Arch. Biochem. Biophys., 216, 337 (1982)) with slight modifications. Assays were performed in 0.1 M phosphate buffer (pH 6.2) containing 0.4 M ammonium sulfate, 10 mM DL-glyceraldehyde, 0.16 mM NADPH and aldose reductase (0.010-0.016 units) in a total volume of 1.0 ml.
  • Hydantoin derivatives of the present invention were examined for acute toxicity. Groups of 5 ICR strain mice were orally administered with compound 7, 13, 14, 15, 16, 17, 19 or 24 of the present invention in a dose of 1 g/kg, and no change was observed in any of the eight groups over the one-week period after the administration.
  • compositions containing at least one of these compounds as active component(s) are useful for the treatment and/or prevention of diabetic complications based on the accumlation of polyol metabolites.
  • hydantoin derivatives provided by the present invention can be employed as pharmaceutical compositions, for example, in the form of pharmaceutical compositions containing hydantoin derivatives together with appropriate pharmaceutically acceptable carrier or medium such as sterilized water, edible oils, and non-toxic organic solvents. They may be mixed with excipients, binders, lubricants, coloring agents, corrigents, emulsifying agents or suspending agents to prepare tablets, powders, syrups, injections, eye drops, suppositories, ointments or inhalants. These agents can be administered either orally or parenterally and the amount of administration may be in the range of 1 to 3000 mg/day and may also be adjusted according to the patient conditions .
  • Example 6 to 25 prepared in a manner similar to Example 1 are summarized in the following table 3 together with corresponding IR and NMR data and melting points.
  • Step 2 To a suspension of the product obtained in Step 1 (37.0 g) and ammonium thiocyanate (24. 3 g) in acetic anhydride (100 ml) was added dropwise anhydrous pyridine (30.5 ml), and the mixture was heated with stirring for 1.5 hours at 70 - 80°C. After cooling to room temperature, the resultant solution was poured into ice (800 g), and the formed precipitate was separated by decantation. The precipitate was washed with water and dried to give 18 -5 g of the objective compound.
  • Example 28 to 52 prepared in a manner similar to Example 26 are summarized in the following table 4 together with corresponding IR and NMR data and melting points.
  • Step 2 (73 ml) was added to a solution of the product obtained in Step 1 (41.4 g) in tetrahydrofuran (730 ml), and the mixture was stirred for 25 minutes at
  • Example 54 and 55 prepared in a manner similar to Example 53 are summarized in the following table 5 together with corresponding IR and NMR data and melting points.
  • a solution of sodium hydroxide (1.6 g) in water (7 ml) was added to a solution of the product obtained in Step 1 (4.22 g) in tetrahydrofuran (70 ml) at room temperature, and the mixture was stirred for 5 minutes at 65 - 75°C.
  • a solution of sodium hydroxide (0.4 g) in water (23 ml) was added to the residue, and the mixture was stirred for 5 hours at 65 - 75oC.
  • the acidified solution was extracted with ethyl acetate (350 ml x 3), the organic layer was washed with water, then saturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, the residue was purified by silica-gel column chromatography to give 5.45 g of the objective compound.
  • Step 1 To a solution of the product obtained in Step 1 (102.3 g) in N,N-dimethylformamide (1.2 1) was added slowly 60% sodium hydride (16.7 g) under ice-cooling, and the mixture was stirred for 1 hour at room temperature. Methyl chlorocarbonate (35.8 g) was added to the above-mentioned mixture followed by stirring for 1 hour at room temperature. After removing the solvent, water (3.5 1) was added to the residue, and the formed precipitate was separated by filtration to give 60.5 g of the objective compound.
  • Formulation C (Powder) Compound 8, 200 g of weight, 790 g of lactose and 10 g of magnesium stearate were weighed and mixed until the mixture became homogeneous to obtain 20% powder preparation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP1988/000843 1987-08-28 1988-08-25 Hydantoin derivatives Ceased WO1989001934A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FI891933A FI97134C (fi) 1987-08-28 1989-04-24 Menetelmä ja välituotteet terapeuttisesti hyödyllisten hydantoiinijohdannaisten valmistamiseksi
NO89891689A NO173059C (no) 1987-08-28 1989-04-24 Analogifremgangsmaate ved fremstilling av terapeutisk aktive hydantoin-derivater
DK207389A DK207389A (da) 1987-08-28 1989-04-28 Hydantoinderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP62214549A JP2764262B2 (ja) 1987-08-28 1987-08-28 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
JP62/214549 1987-08-28

Publications (1)

Publication Number Publication Date
WO1989001934A1 true WO1989001934A1 (en) 1989-03-09

Family

ID=16657578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1988/000843 Ceased WO1989001934A1 (en) 1987-08-28 1988-08-25 Hydantoin derivatives

Country Status (13)

Country Link
US (1) US4914099A (cg-RX-API-DMAC10.html)
EP (1) EP0305947B1 (cg-RX-API-DMAC10.html)
JP (1) JP2764262B2 (cg-RX-API-DMAC10.html)
AT (1) ATE78815T1 (cg-RX-API-DMAC10.html)
AU (1) AU609180B2 (cg-RX-API-DMAC10.html)
CA (1) CA1312083C (cg-RX-API-DMAC10.html)
DE (1) DE3873225T2 (cg-RX-API-DMAC10.html)
DK (1) DK207389A (cg-RX-API-DMAC10.html)
ES (1) ES2042666T3 (cg-RX-API-DMAC10.html)
FI (1) FI97134C (cg-RX-API-DMAC10.html)
GR (1) GR3005392T3 (cg-RX-API-DMAC10.html)
NO (1) NO173059C (cg-RX-API-DMAC10.html)
WO (1) WO1989001934A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004751A (en) * 1987-08-28 1991-04-02 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
JP2673381B2 (ja) * 1990-02-23 1997-11-05 持田製薬 株式会社 糖尿病前症治療剤および/または脂質低下剤
FI902028A7 (fi) * 1988-08-24 1990-04-23 Mochida Pharm Co Ltd Hydantoiinijohdannaisia
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CA2263353C (en) * 1996-08-22 2002-04-23 Dong Wha Pharm. Ind. Co., Ltd. Arylsulfonylimidazolone derivatives as an antitumor agent
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
ATE210639T1 (de) 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
EP1097159B1 (de) 1998-07-16 2002-11-06 Aventis Pharma Deutschland GmbH Phosphin- und phosphonsäurederivate als arzneimittel
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
DE10012401A1 (de) * 2000-03-15 2001-09-27 Sigurd Lenzen Arylsulfonylbenzimidazoione und Arylsulfonylhydantoine als Steigerer der Insulinsekretion
CA2403442A1 (en) * 2000-03-17 2002-09-17 Ajinomoto Co., Inc. Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3384643A (en) * 1965-02-17 1968-05-21 Upjohn Co 1-hydrocarbylsulfonyl-2, 2-dichloro (ordialkoxy)-4, 5-imidazolidine diones
FR6097M (cg-RX-API-DMAC10.html) * 1966-02-17 1968-06-10
FR2308626A1 (fr) * 1975-04-22 1976-11-19 Sumitomo Chemical Co Procede de preparation de n'-sulfonyl-n''-dihalophenylimidazolidinediones et nouveaux produits ainsi obtenus, a activite microbicide contre les champignons et les bacteries se propageant dans les produits industriels
EP0187387A1 (en) * 1984-12-29 1986-07-16 Kaken Pharmaceutical Co., Ltd. Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same
EP0251784A2 (en) * 1986-07-02 1988-01-07 American Home Products Corporation Naphthalenylsulfonylimidazolidinediones and their thioxo analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322565A (ja) * 1986-07-02 1988-01-30 アメリカン・ホ−ム・プロダクツ・コ−ポレイシヨン アルド−スレダクタ−ゼ抑制剤として有用なナフタレニルスルホニルイミダゾリジンジオンおよびそのチオキソ類似体
EP0303863A3 (en) * 1987-08-17 1991-10-23 American Cyanamid Company Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3384643A (en) * 1965-02-17 1968-05-21 Upjohn Co 1-hydrocarbylsulfonyl-2, 2-dichloro (ordialkoxy)-4, 5-imidazolidine diones
FR6097M (cg-RX-API-DMAC10.html) * 1966-02-17 1968-06-10
FR2308626A1 (fr) * 1975-04-22 1976-11-19 Sumitomo Chemical Co Procede de preparation de n'-sulfonyl-n''-dihalophenylimidazolidinediones et nouveaux produits ainsi obtenus, a activite microbicide contre les champignons et les bacteries se propageant dans les produits industriels
EP0187387A1 (en) * 1984-12-29 1986-07-16 Kaken Pharmaceutical Co., Ltd. Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same
EP0251784A2 (en) * 1986-07-02 1988-01-07 American Home Products Corporation Naphthalenylsulfonylimidazolidinediones and their thioxo analogs

Also Published As

Publication number Publication date
DE3873225D1 (de) 1992-09-03
NO891689D0 (no) 1989-04-24
NO173059C (no) 1993-10-20
JP2764262B2 (ja) 1998-06-11
ES2042666T3 (es) 1993-12-16
US4914099A (en) 1990-04-03
NO173059B (no) 1993-07-12
JPS6461465A (en) 1989-03-08
FI891933A7 (fi) 1989-04-24
FI891933A0 (fi) 1989-04-24
CA1312083C (en) 1992-12-29
FI97134C (fi) 1996-10-25
EP0305947A1 (en) 1989-03-08
AU609180B2 (en) 1991-04-26
DE3873225T2 (de) 1993-01-28
NO891689L (no) 1989-04-24
AU2157788A (en) 1989-03-02
EP0305947B1 (en) 1992-07-29
FI97134B (fi) 1996-07-15
ATE78815T1 (de) 1992-08-15
GR3005392T3 (cg-RX-API-DMAC10.html) 1993-05-24
DK207389D0 (da) 1989-04-28
DK207389A (da) 1989-04-28

Similar Documents

Publication Publication Date Title
US4255431A (en) Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion
EP0305947A1 (en) Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use
JP2003128672A (ja) マトリックスメタロプレテイナーゼ阻害剤としての二酸置換ヘテロアリール誘導体
FR2643903A1 (fr) Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
NO162237B (no) Analogifremgangsm te for fremstilling av terapeutisk aktive heterocykliske forbindelser.
FR2673427A1 (fr) Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
HU198060B (en) Process for producing new thienopyridinones and pharmaceutical compositions comprising same
FR2569694A1 (fr) Derives d'ethylenediaminemonoamide, composition pharmaceutique les contenant et utilisation de ces composes a titre d'antidepresseur ou d'antiparkinsonien
WO2007001335A2 (en) Ramoplanin derivatives possessing antibacterial activity
EP0355827B1 (en) Hydantoin derivatives
AU624406B2 (en) 2-aminobenzyl (thiosulfinyl) imidazole derivatives
NZ238648A (en) Substituted benzoxazole derivatives and pharmaceutical compositions
US5912261A (en) Carboxyalkyl heterocyclic derivatives
GB1567662A (en) 5-acyloxy-imidazole-4-carbox-amides
RU2069212C1 (ru) Производные имидазола
US5004751A (en) Hydantoin derivatives
EP0222371A2 (en) Thiazolidine derivatives, process for their preparation and pharmaceutical compositions
US5414006A (en) Arylalkoxythiocoumarins, the preparation thereof and therapeutic compositions containing these
MC593A1 (fr) Nouveaux benzène sulfonyl-semicarbazides et leur préparation
NZ201363A (en) Sulphimine derivatives,and pharmaceutical compositions containing such
US4289768A (en) Phenothiazine derivatives and a process for their preparation
JPH0615539B2 (ja) ヒダントイン誘導体及びそれを有効成分とする医薬組成物
JP2816974B2 (ja) ベンズイミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
EP0068403A2 (en) Cephalosporin compound
JPH0430953B2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DK FI NO

WWE Wipo information: entry into national phase

Ref document number: 891933

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 891933

Country of ref document: FI